By Colin Kellaher

Pfizer Inc. on Tuesday said the European Commission approved Vyndaqel for the treatment of wild-type or hereditary transthyretin amyloidosis in adults with cardiomyopathy, or ATTR-CM.

The New York drug maker said Vyndaqel is the first and only treatment approved in the European Union for the rare, life-threatening disease characterized by the buildup of abnormal deposits of misfolded protein called amyloid in the heart.

Pfizer said prior treatment options for patients with ATTR-CM were restricted to symptom management and, in rare cases, transplant.

The European Medicines Agency's Committee for Medicinal Products for Human Use in December recommended approval Vyndaqel for ATTR-CM.

Write to Colin Kellaher at colin.kellaher@wsj.com

(END) Dow Jones Newswires

February 18, 2020 13:54 ET (18:54 GMT)

Copyright (c) 2020 Dow Jones & Company, Inc.
Grafico Azioni Pfizer (NYSE:PFE)
Storico
Da Mar 2024 a Apr 2024 Clicca qui per i Grafici di Pfizer
Grafico Azioni Pfizer (NYSE:PFE)
Storico
Da Apr 2023 a Apr 2024 Clicca qui per i Grafici di Pfizer